Clinical Trial Update: Safety and Efficacy Study of ULTRASE® MT20 in Participants With Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (PI) [Phase 3]

View source ↗

Summary

Phase 3 safety and efficacy results for ULTRASE MT20 in people with cystic fibrosis and exocrine pancreatic insufficiency, with the study completed and results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis
• Exocrine Pancreatic Insufficiency

Drugs mentioned

• ULTRASE MT20

Snippet

Sponsor: Forest Laboratories | Conditions: Cystic Fibrosis, Exocrine Pancreatic Insufficiency | Phase 3 | Status: COMPLETED | Results posted: 2014-03-12